AI Article Synopsis
- Trastuzumab is a monoclonal antibody used to treat metastatic breast cancer in women with HER2-overexpressing tumors.
- It is generally well tolerated, but rare cardiac side effects, such as new-onset mitral regurgitation, can occur, which may limit its use.
- This study investigates this side effect using two-dimensional speckle tracking echocardiography, highlighting the relationship between cardiac strain and papillary muscle function in affected patients.
Article Abstract
Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the human epidermal growth factor receptor-2. Although trastuzumab is generally well tolerated, cardiac toxicity has occurred as a rare but potentially serious complication that limits its use in some patients. In this study, we detected new-onset mitral regurgitation in trastuzumab-treated patients. To our knowledge, there is no report or survey on new-onset mitral regurgitation during this treatment. We discussed the possible reasons for this newly described side effect of the drug in the light of left ventricular longitudinal global strain and papillary muscle dyssynchrony of the patient by detecting two-dimensional speckle tracking echocardiography.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000323834 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!